Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410159 | 0.86 | BCAT2 (0.49) | BCAT2KEAP1NFE2L2IRAK4PARP1 | |
| SCHEMBL5968855 | 0.84 | IRAK4 (0.47) | BCAT2IRAK4AURKARPS6KB1AURKB | |
| SCHEMBL3663651 | 0.84 | IRAK4 (0.47) | BCAT2IRAK4AURKARPS6KB1AURKB | |
| SCHEMBL6266294 | 0.84 | IRAK4 (0.47) | BCAT2IRAK4AURKARPS6KB1AURKB | |
| Acetic Acid SCHEMBL8910191 | 0.83 | BCAT2 (0.46) | BCAT2KEAP1NFE2L2IRAK4PARP1 | |
| SCHEMBL27511285 | 0.81 | IRAK4 (0.42) | BCAT2KEAP1NFE2L2IRAK4AURKA | |
| SCHEMBL21835618 | 0.81 | IRAK4 (0.42) | BCAT2KEAP1NFE2L2IRAK4AURKA | |
| SCHEMBL20425250 | 0.81 | IRAK4 (0.42) | BCAT2KEAP1NFE2L2IRAK4AURKA | |
| SCHEMBL530130 | 0.81 | TSHR (0.45) | BCAT2KEAP1NFE2L2IRAK4PARP1 | |
| SCHEMBL4301698 | 0.78 | BCAT2 (0.41) | BCAT2KEAP1NFE2L2IRAK4RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | BCAT2 2527/4885KEAP1 1241/4885NFE2L2 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.